GT Biopharma, Inc. (GTBP) stock
GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.18−0.35 (-10.04%)
Close on Nov 17, 2026Market cap $143.45MP/E –Yield –
GT Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
GT Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $3.48M, down 26.0% year over year. For fiscal 2025 it was $3.47M, down 40.1% from the year before. Over ten years it grew 13.3% a year on average. The highest annual figure on record is $9.59M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.47M | -40.1% |
| FY2024 | Dec 31, 2024 | $5.80M | -10.3% |
| FY2023 | Dec 31, 2023 | $6.47M | -26.6% |
| FY2022 | Dec 31, 2022 | $8.81M | -8.1% |
| FY2021 | Dec 31, 2021 | $9.59M | +1877.5% |
| FY2020 | Dec 31, 2020 | $485.00K | -70.9% |
| FY2019 | Dec 31, 2019 | $1.67M | -81.6% |
| FY2018 | Dec 31, 2018 | $9.07M | +749.0% |
| FY2017 | Dec 31, 2017 | $1.07M | +9.5% |
| FY2016 | Dec 31, 2016 | $975.00K | -2.5% |
| FY2015 | Dec 31, 2015 | $1.00M | – |
| FY2014 | Dec 31, 2014 | $0 | – |
| FY2013 | Dec 31, 2013 | $0 | – |
| FY2012 | Dec 31, 2012 | $0 | -100.0% |
| FY2011 | Dec 31, 2011 | $17.00K | -90.5% |
| FY2010 | Dec 31, 2010 | $179.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.06M | +190.6% |
| Q1 FY2026 | Mar 31, 2026 | $413.00K | -62.4% |
| Q4 FY2025 | Dec 31, 2025 | $1.38M | -28.7% |
| Q3 FY2025 | Sep 30, 2025 | $634.00K | -51.5% |
| Q2 FY2025 | Jun 30, 2025 | $363.00K | -79.7% |
| Q1 FY2025 | Mar 31, 2025 | $1.10M | +41.4% |
| Q4 FY2024 | Dec 31, 2024 | $1.93M | +42.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.31M | -4.2% |
| Q2 FY2024 | Jun 30, 2024 | $1.78M | -14.8% |
| Q1 FY2024 | Mar 31, 2024 | $777.00K | -52.9% |
| Q4 FY2023 | Dec 31, 2023 | $1.36M | -52.3% |
| Q3 FY2023 | Sep 30, 2023 | $1.36M | -50.3% |
| Q2 FY2023 | Jun 30, 2023 | $2.10M | +83.9% |
| Q1 FY2023 | Mar 31, 2023 | $1.65M | -20.9% |
| Q4 FY2022 | Dec 31, 2022 | $2.84M | -54.9% |
| Q3 FY2022 | Sep 30, 2022 | $2.74M | +172.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.14M | +78.2% |
| Q1 FY2022 | Mar 31, 2022 | $2.09M | +27.3% |
| Q4 FY2021 | Dec 31, 2021 | $6.30M | +2605.6% |
| Q3 FY2021 | Sep 30, 2021 | $1.01M | +1100.0% |
| Q2 FY2021 | Jun 30, 2021 | $639.00K | +5225.0% |
| Q1 FY2021 | Mar 31, 2021 | $1.64M | +406.2% |
| Q4 FY2020 | Dec 31, 2020 | $233.00K | +2812.5% |
| Q3 FY2020 | Sep 30, 2020 | $84.00K | -87.5% |
| Q2 FY2020 | Jun 30, 2020 | $12.00K | -92.2% |
| Q1 FY2020 | Mar 31, 2020 | $324.00K | -61.2% |
| Q4 FY2019 | Dec 31, 2019 | $8.00K | -99.4% |
| Q3 FY2019 | Sep 30, 2019 | $671.00K | -39.6% |
| Q2 FY2019 | Jun 30, 2019 | $154.00K | -95.3% |
| Q1 FY2019 | Mar 31, 2019 | $834.00K | -76.0% |
| Q4 FY2018 | Dec 31, 2018 | $1.23M | +684.7% |
| Q3 FY2018 | Sep 30, 2018 | $1.11M | +111.2% |
| Q2 FY2018 | Jun 30, 2018 | $3.25M | +1249.0% |
| Q1 FY2018 | Mar 31, 2018 | $3.47M | +2311.8% |
| Q4 FY2017 | Dec 31, 2017 | $157.00K | -37.2% |
| Q3 FY2017 | Sep 30, 2017 | $526.00K | +110.4% |
| Q2 FY2017 | Jun 30, 2017 | $241.00K | – |
| Q1 FY2017 | Mar 31, 2017 | $144.00K | – |
| Q4 FY2016 | Dec 31, 2016 | $250.00K | – |
| Q3 FY2016 | Sep 30, 2016 | $250.00K | – |
See a number that looks wrong?